University Library
  • Login
A gateway to Melbourne's research publications
Minerva Access is the University's Institutional Repository. It aims to collect, preserve, and showcase the intellectual output of staff and students of the University of Melbourne for a global audience.
View Item 
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Medicine, Dentistry & Health Sciences Collected Works
  • Medicine, Dentistry & Health Sciences Collected Works - Research Publications
  • View Item
  • Minerva Access
  • Medicine, Dentistry & Health Sciences
  • Medicine, Dentistry & Health Sciences Collected Works
  • Medicine, Dentistry & Health Sciences Collected Works - Research Publications
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

    The effect of interleukin-22 treatment on autoimmune diabetes in the NOD mouse

    Thumbnail
    Download
    Published version (943.3Kb)

    Citations
    Scopus
    Web of Science
    Altmetric
    3
    3
    Author
    Borg, DJ; Wang, R; Murray, L; Tong, H; Steptoe, RJ; McGuckin, MA; Hasnain, SZ
    Date
    2017-11-01
    Source Title
    Diabetologia
    Publisher
    SPRINGER
    University of Melbourne Author/s
    McGuckin, Michael
    Affiliation
    Medicine Dentistry & Health Sciences
    Metadata
    Show full item record
    Document Type
    Journal Article
    Citations
    Borg, D. J., Wang, R., Murray, L., Tong, H., Steptoe, R. J., McGuckin, M. A. & Hasnain, S. Z. (2017). The effect of interleukin-22 treatment on autoimmune diabetes in the NOD mouse. DIABETOLOGIA, 60 (11), pp.2256-2261. https://doi.org/10.1007/s00125-017-4392-2.
    Access Status
    Open Access
    URI
    http://hdl.handle.net/11343/255647
    DOI
    10.1007/s00125-017-4392-2
    Abstract
    AIMS/HYPOTHESIS: The aim of this study was to determine whether therapy with the cytokine IL-22 could be used to prevent the development of, or treat, autoimmune diabetes in the NOD mouse. METHODS: Six-week-old NOD mice were administered bi-weekly either recombinant mouse IL-22 (200 ng/g) or PBS (vehicle control) intraperitoneally until overt diabetes was diagnosed as two consecutive measurements of non-fasting blood glucose ≥ 11 mmol/l. At this time, NOD mice in the control arm were treated with LinBit insulin pellets and randomised to bi-weekly therapeutic injections of either PBS or IL-22 (200 ng/g) and followed until overt diabetes was diagnosed, as defined above. RESULTS: IL-22 therapy did not delay the onset of diabetes in comparison with the vehicle-treated mice. We did not observe an improvement in islet area, glycaemic control, beta cell residual function, endoplasmic reticulum stress, insulitis or macrophage and neutrophil infiltration as determined by non-fasting blood glucose, C-peptide and histological scoring. Therapeutic administration of IL-22 did not reduce circulating lipopolysaccharide, a marker of impaired gut mucosal integrity. CONCLUSIONS/INTERPRETATION: Our study suggests that, at this dosing regimen introduced either prior to overt diabetes or at diagnosis of diabetes, recombinant mouse IL-22 therapy cannot prevent autoimmune diabetes, or prolong the honeymoon period in the NOD mouse.

    Export Reference in RIS Format     

    Endnote

    • Click on "Export Reference in RIS Format" and choose "open with... Endnote".

    Refworks

    • Click on "Export Reference in RIS Format". Login to Refworks, go to References => Import References


    Collections
    • Minerva Elements Records [45689]
    • Medicine, Dentistry & Health Sciences Collected Works - Research Publications [578]
    Minerva AccessDepositing Your Work (for University of Melbourne Staff and Students)NewsFAQs

    BrowseCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    My AccountLoginRegister
    StatisticsMost Popular ItemsStatistics by CountryMost Popular Authors